Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Victor M MoraImmunopathology Group, Respiratory Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0002-8161-0462
Emilio RodrigoImmunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, RICORS2040 (ISCIII RD21/0005/0010 and RD24/0004/0019), University of Cantabria, 39005 Santander, Spain.ORCID 0000-0002-2845-5272
Elena González-LópezImmunopathology Group, Immunology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0002-0971-3045
Javier Gonzalo Ocejo-VinyalsImmunopathology Group, Immunology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0003-2245-4639
David San SegundoImmunopathology Group, Immunology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0001-5745-9072
David Iturbe-FernándezImmunopathology Group, Respiratory Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0002-5241-266X
Sheila IzquierdoImmunopathology Group, Respiratory Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.
Sandra TelloImmunopathology Group, Respiratory Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.
Marcos López-HoyosImmunopathology Group, Immunology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0003-0562-427X
Maria Mar García-SaizClinical Pharmacology Department, Marqués de Valdecilla University Hospital-IDIVAL, 39005 Santander, Spain.ORCID 0000-0001-5291-3109
Pilar García-BerbelPathological Anatomy Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.
José M CifriánImmunopathology Group, Respiratory Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0003-3682-0142
Funding
Instituto de Salud Carlos III PI20/01710 and RICORS2040 (ISCIII RD21/0005/0010 and RD24/0004/0019)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Increased Eplet Mismatch Load and Reduced Immunosuppressive Exposure Elevate the Risk of Baseline Lung Allograft Dysfunction. · full record | OpenQuestion